AB2 Bio will receive $30 million from Nippon Shinyaku after [...]
FORE Biotherapeutics has completed target enrolment in the primary central [...]
AB2 Bio will receive $30 million from Nippon Shinyaku after [...]
FORE Biotherapeutics has completed target enrolment in the primary central [...]